Illumina Plans to Submit MiSeqDx Assays for Cystic Fibrosis to FDA this Year | GenomeWeb

In a major step toward developing FDA-approved clinical tests on the MiSeq system, Illumina is planning to submit two cystic fibrosis assays to the US Food and Drug Administration for 510(k) clearance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.